CompletedNCT01279213
Paliperidone Added to Clozapine for Resistant Schizophrenia
About this title
Read the official source — NCT01279213Medication studyAges 20–50Argentina
Understand this study
Who was this study for?
Listed age limits: 20 years to 50 years.
- Listed locations
- RosarioSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJanuary 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 70
- Sponsor
- Universidad Nacional de Rosario
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Argentina
- Age range
- From 20 Years to 50 Years
- Official registry ID
- NCT01279213
- Official title
Show the full official title
Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Rosario
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Universidad Nacional de Rosario.
Did this study involve medication?
Yes. The study involved medication, including paliperidone clozapine.
Who was this study for?
Listed age limits: 20 years to 50 years.
